Health consumption and costs reduction in patients with ankylosing spondylitis (AS) treated with etanercept (ETA) for 2 years.

被引：0
|
作者：
Benhamou, Mathilde
Kolta, Sami
Briot, Karine
Roux, Christian
Dougados, Maxime
Fautrel, Bruno
机构：
[1] Univ Paris 05, Cochin Hosp, Dept Rheumatol, Paris, France
[2] Univ Paris 06, Pitie Salpetriere Hosp, Dept Rheumatol, Paris, France
来源：
ARTHRITIS AND RHEUMATISM | 2006年 / 54卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S718 / S719
页数：2
相关论文
共 50 条
  • [31] Fatigue independently predicts different work disability dimensions in etanercept-treated rheumatoid arthritis and ankylosing spondylitis patients
    Druce, Katie L.
    Aikman, Laraine
    Dilleen, Maria
    Burden, Annie
    Szczypa, Piotr
    Basu, Neil
    ARTHRITIS RESEARCH & THERAPY, 2018, 20
  • [32] Fatigue independently predicts different work disability dimensions in etanercept-treated rheumatoid arthritis and ankylosing spondylitis patients
    Katie L. Druce
    Laraine Aikman
    Maria Dilleen
    Annie Burden
    Piotr Szczypa
    Neil Basu
    Arthritis Research & Therapy, 20
  • [33] LONG-TERM OUTCOME OF PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS WITH ETANERCEPT - SUSTAINED EFFICACY AND SAFETY AFTER 7 YEARS
    Baraliakos, X.
    Haibel, H.
    Fritz, C.
    Listing, J.
    Heldmann, F.
    Braun, J.
    Sieper, J.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2012, 30 (04) : 638 - 638
  • [34] DRUG SURVIVAL AND CLINICAL EFFICACY OF 7 YEARS ETANERCEPT TREATMENT IN PATIENTS WITH ANKYLOSING SPONDYLITIS: RESULTS FROM THE GLAS COHORT
    Arends, S.
    Brouwer, E.
    Wink, F.
    Bos, R.
    Maas, F.
    Bootsma, H.
    van der Veer, E.
    Spoorenberg, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 283 - 283
  • [35] Retention Rate of Adalimumab, Etanercept, and Infliximab at 5 Years in Patients with Ankylosing Spondylitis: Report from the Rhumadata Computerized Database
    Choquette, Denis
    Sauvageau, Diane
    Raynauld, Jean-Pierre
    JOURNAL OF RHEUMATOLOGY, 2013, 40 (06) : 994 - 994
  • [36] Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept:: Clinical and magnetic resonance imaging data
    Baraliakos, X
    Brandt, J
    Listing, J
    Haibel, H
    Sörensen, H
    Rudwaleit, M
    Sieper, J
    Braun, J
    ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2005, 53 (06): : 856 - 863
  • [37] Association of health care utilization and costs with patient-reported outcomes in patients with ankylosing spondylitis
    Ogdie, Alexis
    Hwang, Mark
    Veeranki, Phani
    Portelli, Alexandria
    Sison, Steven
    Shafrin, Jason
    Pedro, Sofia
    Kim, Nina
    Yi, Esther
    Michaud, Kaleb
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2022, 28 (09): : 1008 - 1020
  • [38] ABSENCE OF RADIOGRAPHIC PROGRESSION OF HIP ARTHRITIS IN PATIENTS WITH ANKYLOSING SPONDYLITIS TREATED WITH INFLIXIMAB FOR 6 YEARS
    Konsta, M.
    Bournia, V. K.
    Sfikakis, P. P.
    Karras, D.
    Iliopoulos, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 249 - 250
  • [39] Socioeconomic consequences for patients with active ankylosing spondylitis treated for two years with infliximab in a clinical trial
    Brandt, J
    Listing, J
    Krause, A
    Gromnica-Ihle, E
    Kellner, H
    Schneider, M
    Sörensen, H
    Zeidler, H
    Alten, R
    Reddig, J
    Rudwaleit, M
    Sieper, J
    Braun, J
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 256 - 257
  • [40] The natural history of total hip replacements in ankylosing spondylitis: 309 hips in 156 patients followed for a mean of 14 years.
    Calin, A
    Sweeney, S
    Gupta, R
    ARTHRITIS AND RHEUMATISM, 1999, 42 (09): : S402 - S402
12345